Epeius Biotechnologies' Tumor Targeted Rexin G Receives FDA Orphan Drug Designation For The Treatment Of Osteosarcoma (Medical News Today)
Epeius Biotechnologies Corporation announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma.

APP Pharma gets US FDA nod for additional dosages of Granisetron HCl injection (PharmaBiz)
APP Pharmaceuticals, Inc., a leading manufacturer of multi-source and branded injectable pharmaceutical products, has received final approvals from the US Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Granisetron hydrochloride injection, 1 mg/mL, 1 mL single dose, and 1mg/mL, 4mL multiple dose vials, the generic equivalent of Hoffmann-LaRoche's Kytril ...